Shire enters into agreement with Sanquin for CINRYZE

Download PDF Copy

Reviewed

Shire plcAug 25 2015

The company enters into new agreement with Sanquin

Shire plc (LSE: SHP, NASDAQ: SHPG) announced today it has entered into an agreement with Sanquin Blood Supply, the manufacturer of CINRYZE® (C1 esterase inhibitor [human]), providing Shire access to its manufacturing technology and allowing Shire to source additional manufacturers to meet the growing demand for CINRYZE.

"We wanted the freedom to operate and expand in a way that makes strategic sense for our business," said Flemming Ornskov, M.D., CEO, Shire. "When Shire acquired ViroPharma in January 2014, we inherited an arrangement under which Sanquin was the exclusive manufacturer for CINRYZE. We're pleased that Sanquin was open to expanding our partnership and agreeing to support us as we increase production options for this important therapy."

The specific terms of the agreement are confidential, but involve payments to Sanquin on achievement of certain milestones, including a successful technical transfer to a second source manufacturer. Sanquin will continue to serve as a key partner with Shire to increase global supply of CINRYZE.

Source:

Shire plc

Posted in: Business / Finance | Pharmaceutical News

Comments (0)

Download PDF Copy

Suggested Reading

Beetroot juice lowers blood pressure in older adults by reshaping oral bacteria

AI and routine lab tests offer a more accurate prediction of genetic disease risk

Daily walking reduces the chances of chronic low back pain

Study finds links between human genetic variation, gut mycobiome, and chronic disease risk

Breakthrough reveals how viruses efficiently pack genetic material

Male and female bovine embryos show distinct development paths

Genetic testing of IVF-created embryos could help more women over 35 have a baby sooner

Researchers uncover a promising new therapeutic target for Barth syndrome

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

(Logout)

Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.